Jan 13 (Reuters) - Anavex Life Sciences Corp :
* NEW PHASE IIB/III CLINICAL DATA DEMONSTRATES OVER THREE YEARS OF CONTINUOUS TREATMENT WITH ORAL BLARCAMESINE TO SIGNIFICANTLY BENEFIT EARLY ALZHEIMER’S DISEASE PATIENTS
* ANAVEX LIFE SCIENCES CORP: TOPLINE ATTENTION-AD TRIAL: PATIENTS SHOWED IMPROVED COGNITION AND FUNCTION OVER THREE YEARS
* ANAVEX LIFE SCIENCES CORP: BLARCAMESINE EXHIBITED A FAVORABLE SAFETY PROFILE WITH NO TREATMENT-RELATED DEATHS
Source text: Further company coverage:
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.